Zolron Tablet SR is a sustained-release formulation containing a total of 1000 mg of Paracetamol, divided into 300 mg immediate-release and 700 mg extended-release components, designed to provide effective and prolonged analgesic and antipyretic effects. Paracetamol, a widely used non-opioid analgesic and antipyretic agent, acts centrally to inhibit prostaglandin synthesis, thereby alleviating mild to moderate pain and reducing fever. The sustained-release mechanism of Zolron Tablet SR ensures a steady plasma concentration of Paracetamol, enhancing patient compliance by reducing dosing frequency while maintaining therapeutic efficacy over an extended period. This formulation is indicated for the management of conditions such as headache, dental pain, musculoskeletal pain, osteoarthritis, and fever associated with various infections. It is generally well-tolerated, with a low incidence of adverse effects when used at recommended doses; however, caution is advised in patients with hepatic impairment or chronic alcohol use due to the risk of hepatotoxicity. Zolron Tablet SR should be administered as directed by a healthcare professional, and patients are advised to avoid concomitant use of other Paracetamol-containing products to prevent overdose. This medication is contraindicated in individuals with known hypersensitivity to Paracetamol or any excipients in the formulation.